PE20211141A1 - SALMONELLA ENTERITIDIS RECOMBINANTE AND ITS USE AS A SWINE VACCINE - Google Patents

SALMONELLA ENTERITIDIS RECOMBINANTE AND ITS USE AS A SWINE VACCINE

Info

Publication number
PE20211141A1
PE20211141A1 PE2019002588A PE2019002588A PE20211141A1 PE 20211141 A1 PE20211141 A1 PE 20211141A1 PE 2019002588 A PE2019002588 A PE 2019002588A PE 2019002588 A PE2019002588 A PE 2019002588A PE 20211141 A1 PE20211141 A1 PE 20211141A1
Authority
PE
Peru
Prior art keywords
salmonella enteritidis
strain
type
porcine circovirus
dwaal
Prior art date
Application number
PE2019002588A
Other languages
Spanish (es)
Inventor
Diaz Manolo Clemente Fernandez
Eguis Jorge Eduardo Bendezu
Ruiz Sandra Steffany Morales
Original Assignee
Farm Veterinarios S A C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farm Veterinarios S A C filed Critical Farm Veterinarios S A C
Priority to PE2019002588A priority Critical patent/PE20211141A1/en
Priority to PCT/PE2020/000013 priority patent/WO2021125982A1/en
Priority to MX2022007508A priority patent/MX2022007508A/en
Priority to ARP200103508A priority patent/AR120779A1/en
Publication of PE20211141A1 publication Critical patent/PE20211141A1/en
Priority to ECSENADI202234742A priority patent/ECSP22034742A/en
Priority to CONC2022/0008650A priority patent/CO2022008650A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a una cepa de Salmonella enteritidis 3934vac a la cual se le ha delecionado el gen waaL para obtener un fenotipo rugoso (3934vac DwaaL), el procedimiento de obtencion y los oligos utilizados; con el objetivo de reducir la toxicidad y mantener la inmunogenicidad para su aplicacion como vacuna. Otro aspecto de la presente invencion se refiere a una cepa de Salmonella enteritidis 3934vac DwaaL, es decir de tipo rugosa, la cual ha sido modificada para expresar el xeno-antigeno de la proteina de la capside (CAP) del circovirus porcino tipo 2. Ademas, el procedimiento para la obtencion de una cepa de Salmonella enteritidis 3034 vac DwaaL que expresa un xeno-antigeno de la proteina de la capside (CAP) del circovirus porcino tipo 2. La invencion comprende tambien el desarrollo de una nueva vacuna porcina, viva, recombinante, eficaz e inocua contra circovirus porcino tipo 2 desarrollada via un proceso de insercion e integracion de xeno-antigeno de la proteina de la capside (CAP) del circovirus porcino tipo 2 en el cromosoma y plasmido de una cepa atenuada y no patogenica de la bacteria Salmonella enteritidisThe present invention refers to a strain of Salmonella enteritidis 3934vac in which the waaL gene has been deleted to obtain a rough phenotype (3934vac DwaaL), the procedure for obtaining and the oligos used; with the objective of reducing toxicity and maintaining immunogenicity for its application as a vaccine. Another aspect of the present invention refers to a strain of Salmonella enteritidis 3934vac DwaaL, that is to say of the rough type, which has been modified to express the xeno-antigen of the capsid protein (CAP) of type 2 porcine circovirus. , the procedure for obtaining a strain of Salmonella enteritidis 3034 vac DwaaL that expresses a xeno-antigen of the capsid protein (CAP) of porcine circovirus type 2. The invention also includes the development of a new live porcine vaccine, recombinant, effective and safe against porcine circovirus type 2 developed via a process of insertion and integration of xeno-antigen of the capsid protein (CAP) of porcine circovirus type 2 in the chromosome and plasmid of an attenuated and non-pathogenic strain of the Salmonella enteritidis bacteria

PE2019002588A 2019-12-19 2019-12-19 SALMONELLA ENTERITIDIS RECOMBINANTE AND ITS USE AS A SWINE VACCINE PE20211141A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PE2019002588A PE20211141A1 (en) 2019-12-19 2019-12-19 SALMONELLA ENTERITIDIS RECOMBINANTE AND ITS USE AS A SWINE VACCINE
PCT/PE2020/000013 WO2021125982A1 (en) 2019-12-19 2020-11-05 Recombinant salmonella enteritidis and use thereof as a vaccine for pigs
MX2022007508A MX2022007508A (en) 2019-12-19 2020-11-05 Recombinant salmonella enteritidis and use thereof as a vaccine for pigs.
ARP200103508A AR120779A1 (en) 2019-12-19 2020-12-17 RECOMBINANT SALMONELLA ENTERITIDIS AND ITS USE AS A SWINE VACCINE
ECSENADI202234742A ECSP22034742A (en) 2019-12-19 2022-03-30 RECOMBINANT SALMONELLA ENTERITIDIS AND ITS USE AS A SWINE VACCINE
CONC2022/0008650A CO2022008650A2 (en) 2019-12-19 2022-06-21 Recombinant salmonella enteritidis and its use as a swine vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PE2019002588A PE20211141A1 (en) 2019-12-19 2019-12-19 SALMONELLA ENTERITIDIS RECOMBINANTE AND ITS USE AS A SWINE VACCINE

Publications (1)

Publication Number Publication Date
PE20211141A1 true PE20211141A1 (en) 2021-06-25

Family

ID=76478846

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002588A PE20211141A1 (en) 2019-12-19 2019-12-19 SALMONELLA ENTERITIDIS RECOMBINANTE AND ITS USE AS A SWINE VACCINE

Country Status (6)

Country Link
AR (1) AR120779A1 (en)
CO (1) CO2022008650A2 (en)
EC (1) ECSP22034742A (en)
MX (1) MX2022007508A (en)
PE (1) PE20211141A1 (en)
WO (1) WO2021125982A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150959A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
CN103739717B (en) * 2014-01-15 2015-07-22 北京市农林科学院 Recombinant protein subunit vaccine for resisting porcine circovirus serotype 2
KR102055215B1 (en) * 2015-12-28 2020-01-22 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 Porcine circovirus type 2 capsid protein and method of preparing a pharmaceutical composition comprising the same
JP2019507784A (en) * 2016-03-07 2019-03-22 ヴァージニア テック インテレクチュアル プロパティーズ，インコーポレーテッド Chimeric porcine circovirus type 2 (PCV2) vaccine
PE20171768A1 (en) * 2017-06-12 2017-12-21 Farm Veterinarios S A C OBTAINING A ROUGH TYPE SALMONELLA ENTERITIDIS AND ITS GENETIC MODIFICATIONS FOR USE AS A VACCINE AVIAN
CN109125719B (en) * 2017-06-19 2022-06-14 普莱柯生物工程股份有限公司 Immunogenic composition containing porcine circovirus type 3 and porcine circovirus type 2 antigens and application thereof
CN107337718B (en) * 2017-06-20 2021-06-01 山东省农业科学院畜牧兽医研究所 Gene for coding porcine circovirus type 2Cap protein and application thereof
CN107841507B (en) * 2017-11-23 2021-05-11 南京农业大学 Efficiently expressed porcine circovirus type 2 Cap-cell-penetrating peptide fusion protein gene and application thereof

Also Published As

Publication number Publication date
WO2021125982A1 (en) 2021-06-24
MX2022007508A (en) 2022-07-11
AR120779A1 (en) 2022-03-16
CO2022008650A2 (en) 2022-06-30
ECSP22034742A (en) 2022-11-30

Similar Documents

Publication Publication Date Title
CO2019012289A2 (en) Obtaining a rough type salmonella enteritidis and its genetic modifications for use as an avian vaccine
AR069882A1 (en) PORCINO CIRCOVIRUS, ISOLATED NUCLEIC ACID MOLECULA THAT CODIFIES IT, IMMUNOGENIC COMPOSITION THAT UNDERSTANDS IT, VECTOR THAT UNDERSTANDS AT LEAST ONE EXCELLED NUCLEIC ACID MOLECULA THAT CODIFIES A PROMOTION OF PORCINE OPENING EFFECT
PE20061287A1 (en) IMMUNOGENIC COMPOSITION INCLUDING gE VZV AND THE ADJUVANT TH-1
BR112018013387A2 (en) recombinant vaccination vector, mva virus, vaccine or pharmaceutical composition and kit
BR112017001310A2 (en) coronavirus
CO6531435A2 (en) NEW FORMULATIONS OF VACCINE THAT INCLUDES ADJUVANTS CONTAINING SAPONINA
EA201800494A1 (en) VACCINES AGAINST CHIMERIC CIRCOVIRUS OF PIGS TYPE 2 (PCV2)
AR079526A1 (en) VACCINE MULTIVALLY AGAINST SWINE TESCHOVIRUS AND OTHER ORGANIZATIONS THAT CAUSE DISEASES IN THE PIGS
CO2018003460A2 (en) Vaccines of virus-like particles (vlp) against canine parvovirus (cpv) and their uses
CO2018010874A2 (en) Live attenuated Zika virus vaccine
CL2018001946A1 (en) Attenuated viruses of infectious bronchitis.
AR103427A1 (en) VACCINE AGAINST AFTOSE FEVER
AR080313A1 (en) COMPOSITIONS OF RECOMBINANT CANINE MACHINE VIRUS (CDV) AND ITS USES
PE20140871A1 (en) COMPOSITIONS AND METHODS OF VACCINE FOR BOVINE VIRAL DIARRHEA TYPE 1b
CL2021003211A1 (en) A modified live strain of porcine reproductive and respiratory syndrome virus (prrs), a vaccine comprising it and its use to treat prrs type ii. (divisional application no. 2123-2018)
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
AR101468A1 (en) ADENOVIRUS AVIAR SEROTYPE RECOMBINING VECTOR VACCINE 9
CO2023009285A2 (en) HIV vaccines and methods of use
CO2022004470A2 (en) Recombinant herpesvirus of turkeys vectors expressing avian pathogen antigens and uses thereof
MX2021011913A (en) Inactivated virus compositions and zika vaccine formulations.
CO2018001339A2 (en) Avian adenovirus 9 vector system (fadv-9) and associated methods
CO2023000493A2 (en) Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
PE20211141A1 (en) SALMONELLA ENTERITIDIS RECOMBINANTE AND ITS USE AS A SWINE VACCINE
AR066823A1 (en) INCREASE IN PLANTS PERFORMANCE BY MODULATION OF GARP TRANSMISSION ZMRR10-P FACTOR
CR20170280A (en) VACCINE COMPOSITIONS FOR DENGUE VIRUSES AND METHODS OF THE SAME USE